About LIM/homeobox protein Lhx1
LIM/homeobox protein Lhx1 (LHX1) is a protein
from Homo sapiens identified by UniProt accession
P48742, 406 residues long.
MolForge cross-references it against 0 known binders and
77 disease associations.
Target properties
| Protein name | LIM/homeobox protein Lhx1 |
| UniProt accession | P48742 |
| Gene | LHX1 |
| Organism | Homo sapiens |
| Length | 406 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (77)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.56
- brain volume measurement · score 0.34
- metabolite measurement · score 0.26
- high density lipoprotein cholesterol measurement · score 0.22
- physical activity · score 0.22
- genetic disorder · score 0.19
- macrophage inflammatory protein 1b measurement · score 0.18
- pulmonary tuberculosis · score 0.07
- thyroid volume · score 0.05
- 46,XX ovotesticular disorder of sex development · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P48742-F1 | alphafold | PREDICTED | 66.73 | — |
Amino-acid sequence (406 residues)
MVHCAGCKRP ILDRFLLNVL DRAWHVKCVQ CCECKCNLTE KCFSREGKLY CKNDFFRCFG TKCAGCAQGI SPSDLVRRAR SKVFHLNCFT CMMCNKQLST GEELYIIDEN KFVCKEDYLS NSSVAKENSL HSATTGSDPS LSPDSQDPSQ DDAKDSESAN VSDKEAGSNE NDDQNLGAKR RGPRTTIKAK QLETLKAAFA ATPKPTRHIR EQLAQETGLN MRVIQVWFQN RRSKERRMKQ LSALGARRHA FFRSPRRMRP LVDRLEPGEL IPNGPFSFYG DYQSEYYGPG GNYDFFPQGP PSSQAQTPVD LPFVPSSGPS GTPLGGLEHP LPGHHPSSEA QRFTDILAHP PGDSPSPEPS LPGPLHSMSA EVFGPSPPFS SLSVNGGASY GNHLSHPPEM NEAAVW
Explore LIM/homeobox protein Lhx1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets